Revolutionize GBM Treatment by Advancing the Development & Delivery of Effective Therapeutics
The huge unmet need for glioblastoma therapies reinforces the critical importance for the community to unite at the 5th Glioblastoma Drug Development Summit in Boston, March 2024 to collaboratively address the recurring barriers to treatment success.
With promising clinical readouts from a range of therapeutic modalities, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy, there is more promise within the GBM space than ever before.
This is the only industry-led, therapeutic agnostic event which brings together large pharma, biotech, neurosurgeons and world-renowned academics alongside investors with a shared mission: revolutionizing glioblastoma and CNS tumour drug development.
Join this year’s pioneering line up of companies including Mimivax, Polaris, Day One Biopharmaceuticals, Novartis, Bristol-Myers Squibb and 25+ more.
The future of glioblastoma treatment starts here.
The 2024 World-Class Speaker Faculty Includes:
Previous Attendees Include:
2024 Partner:
What past attendees had to say:
“Really good mix of content and participants - companies, researchers, clinicians, and investors. Appealing format, with great opportunities for interaction and networking”
James Garner, Chief Executive Officer, Kazia Therapeutics
“This is the most useful meeting of the year for learning the latest trials for glioblastomas and future directions”
Patrick Wen, Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute
“Excellent content, highly qualified speakers, and network was made convenient and accessible”
Mike Choukas, Co-founder and Chief Executive Officer, Autem Therapeutics
“This was a highly well-organized, engaging and unique for this type of conference as it was science driven with excellent speakers and panel members”
Senior Director, Inovio Pharmaceuticals
“GBM DDS is the definitive meeting on GBM and an excellent opportunity to understand the length and breadth of drug development activity in this disease”
Chief Executive Officer, Kazia Therapeutics
What our upcoming speakers have to say:
“This is a great opportunity to meet with like-minded individuals who are interested in the development of drugs for the treatment of glioblastoma.”
John Bomalaski, Executive Vice President, Medical Affairs, Polaris Pharmaceuticals
“This is a pivotal time for new drug/treatment/diagnostic development for hard-to-treat brain tumors. Pioneering companies can make huge positive impacts for patients with these devastating diseases and have commercial success.”
Kirk Tanner, Chief Scientific Officer, National Brain Tumor Society